An international consensus guideline in Lancet Oncology, developed by 54 experts from 46 centres in 18 countries and endorsed by 17 oncology organisations, addresses de novo metastatic nasopharyngeal carcinoma — historically treated as incurable. It makes 32 recommendations, 29 of them strong.
The central recommendation is that medically fit patients with no more than three metastatic lesions in two or fewer organs, either at diagnosis or after responding to systemic therapy, should be offered curative-intent treatment. That means multimodality care: immunochemotherapy, locoregional radiotherapy to the primary and neck, metastasis-directed therapy, and maintenance.
This shifts a group of patients from palliative to curative pathways. Nasopharyngeal carcinoma is endemic in parts of north-east India, where patients often present late; identifying the oligometastatic subset and referring to a centre that can deliver all components is the practical step.
- Offer curative-intent treatment to fit patients with up to three metastases in no more than two organs
- Reassess after systemic therapy — responders down to this burden also qualify
- Plan multimodality care: immunochemotherapy, locoregional radiotherapy, metastasis-directed therapy and maintenance
- Refer to a centre able to deliver all components
- Stage carefully, as eligibility depends on lesion count
Why it matters
It moves a group of patients who would have received palliative care onto a pathway aiming for cure.
Don't overread it
This is a consensus guideline; several recommendations rest on expert agreement rather than randomised evidence.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free